NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Ulixertinib (Primary)
- Indications Neuroblastoma; Non-Hodgkin's lymphoma; Solid tumours
- Focus Therapeutic Use
- Acronyms A Pediatric MATCH Treatment Trial
- 14 Nov 2019 Status changed from recruiting to suspended.
- 14 Oct 2019 Status changed from suspended to recruiting.
- 09 Sep 2019 Status changed from recruiting to suspended.